Doctor Didier Raoult Part I: Where We Are Now -The Chloroquine Wars Part XXV
Over 10,000 patients,a fatality rate more than 97% LOWER than France’s – an exceptional case for early treatment with a drug regimen including HCQ & AZM.
Over 10,000 patients,a fatality rate more than 97% LOWER than France’s – an exceptional case for early treatment with a drug regimen including HCQ & AZM.
Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.
Just as fast as new cases materialized so has the decline thanks in part to a coordinated public health strategy that includes proactive testing, home visits, and medication kits that include ivermectin.
“The significant decline is a tremendous achievement in the fight against COVID-19 and further bolsters our appeal to undertake mass distribution of ivermectin to our people.”
With ivermectin now on the national Indian COVID-19 list of recommended treatments for COVID-19, a few states have gone to the next level and included the low-cost, generic drug approved throughout the world as a parasite fighter as a prophylactic targeting SARS-CoV-2, the virus behind COVID-19.
The kits distributed included ivermectin, aspirin and paracetamol. Between the end of November 2020 and the end of January 2021, more than 200,000 people tested positive for COVID, and of these, nearly 80,000 used the ivermectin kits. Results showed up to 76% reduction in hospitalization in the group that was taking ivermectin.
Zero patients in the ivermectin group that became hospitalized (as compared to 3 in the control group), the results were overall impressive.
In our carefully considered opinion, the available data on Ivermectin is quite adequate. There is no need to await the outcome of further trials. Any call for local trials prior to approval is unnecessary, as neither time, resources, nor ethical approval would permit.
“Tackling the pandemic probably requires, in addition to a vaccine, a preventive or early-acting drug. This drug also helps especially in a situation where vaccine coverage threatens to remain too low for herd immunity,” said Väänänen.
A medical doctor and scientist, Dr Urso is one of the most prominent C19 doctors in the US. Since March 2020, he has treated hundreds of patients at home, on an ambulatory basis. In this interview, he tells us about his experience, about C19 in Texas and about the America’s Frontline Doctors movement.
Doctors have found safe, effective and inexpensive treatments that work well in preventing and treating patients with COVID-19 like Ivermectin that’s been used safely for more than 30 years.
But the government has not supported the use of this effective drug. In fact, there are other therapies like hydroxychloroquine, vitamins D and C and zinc that physicians have found to be safe and effective in preventing and treating COVID.
But while political psychology did its thing, making HCQ a no go zone for many physicians, Tyson and his staff simply treated patients according to whatever seemed to work, using HCQ as a primary option. And work it did.
Both Goa and Karnataka are rolling out mass Ivermectin programs in a bid to reduce infection, transmission, and death rates associated with COVID-19. TrialSite reported two days ago that the State of Goa embraced the national Ivermectin guidelines, and as reported in The Mint and other outlets, Vishwajit Rane, Goa’s Health Minister, declared that all people 18 years and up would have access to the generic drug regardless of COVID-19 status in an aggressive bid to lower infection rates and total deaths associated with SARS-CoV-2.
Today, the health experts tasked at the political levels of the United States (and by chance those nations closest to its sphere of influence) are failing us by dismissing an avalanche of evidence of effective empiric COVID-19 treatments, primarily at the early stages of disease.
We are very honored to present this interview of Dr Vladimir Zelenko, the father of outpatient treatment for COVID-19 in North America. Dr Zelenko shares his own experience with COVID-19 as a patient, as he is recovering from a severe form of the disease.
He also talks about his cancer and how he was able to go through this dramatic episode of his life. Then, he presents his perspectives about outpatient treatment as practiced today and the evolution of the pandemic, among other topics.
Famous actor, Louis Gosset Jr. and his physician, Dr. Bruce Boros, share their experience with a life saving treatment against Covid.
At this point, continuing the use of Ivermectin has proven safe and we see no reason to stop this drug, which seems to have not only inhibited our second wave but so far prevented a third one.
“It [nomination for the Nobel Peace Prize] gives credibility to the message,” Dr. Zelenko said. “Which is, treat Covid-19 early and live.”
n a recent interview, Dr. Stone recently shared that while the death rate climbed much higher in January, again peaking at 70 deaths on the 25th of that month, Official authorization for the use of ivermectin was granted a day later.
A month later, the number of deaths fell to zero. Again, the correlation here along with Dr. Stone’s direct clinic experience is ivermectin sales. Over 500,000 doses of the generic, FDA-approved drug were administered from December through February. This compares to 1,057 bottles turned over in January 2020.
If you were going to try and design a drug, for the disease that we call COVID-19, you would want something with heavy anti-viral properties, as well as anti-inflammatory properties.
When you think about that, it’s hard to come up with a better drug for Covid than ivermectin. It literally does both of those things simultaneously, and it’s one of the safest drugs known to man.
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. Prof. Héctor Carvallo shares his experiences with using ivermectin for long covid in Argentina.
The International Ivermectin for Covid Conference: Dr. Wasif Khan presents his published ivermectin trial and his experience with using ivermectin in Bangladesh.
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. Prof. Pierre Kory discusses current protocols for covid-19 prevention and treatment.
The International Ivermectin for Covid Conference: Professor Eli Schwartz shares data and conclusions from his Israeli randomised controlled trial of ivermectin in mild to moderate covid-19.
The first-ever conference focusing on the use of ivermectin (IVM) as a prophylaxis and treatment for covid-19 was held online April 24-25 2021. Dr Tina Peers, UK GP describes her real-world experiences treating Long Covid.
The International Ivermectin for Covid Conference: Dr. David Chesler shares his experience of using ivermectin to prevent and treat covid-19 infection amongst care home residents.
Medical experts from around the world joined together to present the very latest real world research on repurposing ivermectin that has the ability to transform global efforts to fight the pandemic. Mr. Andrew Bryant provides an overview of ongoing trials and what they may add to the evidence base.
Dr. Tess Lawrie presents the latest systematic review evidence from RCTs and a selection of resource, equity, acceptability and feasibility considerations related to ivermectin use for COVID-19
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. In this talk, speaker Dr. Mobeen Syed provides an overview of ivermectin and how it works against covid-19.
So, what’s different between Maharashtra and Delhi with respect to the rest of India and South Asia? Instead of relying on HCQ and IVM, many doctors and health officials in Maharashtra and Delhi pushed the expensive and profitable remdesivir drug. Due to its cost and recommended time of usage, remdesivir is not used either as a prophylaxis or for early outpatient treatment. And unlike the cheap and easy-to-produce HCQ and IVM, remdesivir is difficult to replace when it runs out.
With a surge of SARS-CoV-2 infections and a vaccination drive totaling 1.3 million, the nation’s leadership faces an uphill battle when factoring in their total population of 108 million. Hence the growing interest in ivermectin and the request of hospitals for access to the drug for compassionate use.
Every viral illness starts that way. The more it’s allowed to progress, the more it takes over the cells and replicates itself. That’s why this virus absolutely had to be treated early to prevent those damages. Primarily what has killed people with COVID is a delay to treatment, and allowing the exaggerating inflammatory response and blood clotting response to take hold in the body.
MANILA, Philippines — Another private hospital was given a compassionate special permit (CSP) to use Ivermectin as treatment for COVID-19 patients, the Food and Drug Administration (FDA) said yesterday.
This disease is very manageable & easy to treat. They censor us because we tell the truth – they don’t want us to treat people. They want to sell vaccines.
In an interview with Alan Jones, Craig Kelly MP discusses the vaccine rollout mishaps and yet again, rightfully points out the myriad of medical specialists around the world who support the use of ivermectin for the prophylaxis and treatment of their Covid-19 patients with the backup of extensive positive data.
Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.
FLCCC Weekly Update: “Big Science vs Little Science”—April 14, 2021 Drs. Jose Morgenstern and Jose Redondo of the Dominican Republic share their new ivermectin study and tell the story of how they discovered the efficacy of ivermectin in April, 2020.
Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.
The case involving John W. Swanson, a farmer from Stafford in Genesee County, is the latest of several in which judges have ordered local hospitals to give Ivermectin to patients suffering from the virus.
An Internist, cardiologist and professor of medicine, Dr McCollough treats covid patients and was involved in two major studies indicating that treatment is the key to getting covid under control.